Gyre Therapeutics (GYRE) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Obsidian Therapeutics is the larger company by market cap ($756.1 million vs $716.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | OBX |
|---|---|---|
| Share price | $6.76 | $12.24 |
| Market cap | $716.79M | $756.10M |
| 1-day change | -3.98% | -7.27% |
| YTD return | -4.25% | — |
| 1-year return | -7.40% | — |
| 5-year return | -88.73% | — |
| Forward P/E | 112.67 | — |
| EPS (TTM) | $-0.25 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $49.97 |
| 52-week low | $5.44 | $12.07 |
| Distance from 52-week high | -28.24% | -75.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.18% | +218.63% |
| Average volume | 105.93K | 367.35K |
| Shares outstanding | 106.03M | 61.77M |
| Employees | 625 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
GYRE vs OBX FAQ
Which is bigger, Gyre Therapeutics or Obsidian Therapeutics?
Obsidian Therapeutics (OBX) is larger, with a market capitalization of $756.10M compared with $716.79M for Gyre Therapeutics (GYRE).
Are Gyre Therapeutics and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.